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Purpose: To evaluate the efficacy of proton beam therapy (PBT) for pediatric patients with advanced
neuroblastoma.
Methods: PBT was conducted at 21 sites in 14 patients with neuroblastoma from 1984 to 2010. Most patients were
difficult to treat with photon radiotherapy. Two and 6 patients were classified into stages 3 and 4, respectively, and
6 patients had recurrent disease. Seven of the 8 patients who received PBT as the initial treatment were classified as
the high risk group. Twelve patients had gross residual disease before PBT and 2 had undergone intraoperative
radiotherapy before PBT. Five patients received PBT for multiple sites, including remote metastases. Photon
radiotherapy was used in combination with PBT for 3 patients. The PBT doses ranged from 19.8 to 45.5 GyE
(median: 30.6 GyE).
Results: Seven patients are alive with no evidence of disease, 1 is alive with disease progression, and 6 died due to
the tumor. Recurrence in the treatment field was not observed and the 3-year locoregional control rate was 82%.
Severe acute radiotoxicity was not observed, but 1 patient had narrowing of the aorta and asymptomatic vertebral
compression fracture at 28 years after PBT, and hair loss was prolonged in one patient.
Conclusion: PBT may be a better alternative to photon radiotherapy for children with advanced neuroblastoma,
and may be conducted safely for patients with neuroblastoma that is difficult to manage using photon beams.
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Neuroblastoma is the most common extracranial solid
tumor in children. Half of newly diagnosed patients
present with high risk disease that is widely metastatic and
has large and invasive lesions in the advanced stage. Ag-
gressive treatment is conducted in these cases because they
are highly sensitive to radiotherapy and chemotherapy.
However, despite recent progress with systemic therapy,
the treatment outcome in high risk neuroblastoma is poor
[1-5]. Advanced neuroblastoma also often recurs and the
prognosis after recurrence is extremely poor [6-8], with
Garaventa et al. finding survival rates of only 6.6% and
1.5% in patients with progression and relapse disease [7].
Recently, the superiority of the dose distribution in proton* Correspondence: hsakurai@pmrc.tsukuba.ac.jp
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reproduction in any medium, provided the orbeam therapy (PBT) has been shown compared to the pho-
ton dose distribution especially in children [9-13]. How-
ever, to our knowledge, there are few reports on clinical
outcomes after PBT. [14] We have mainly treated patients
with advanced high risk neuroblastoma or recurrent dis-
ease using PBT since 1984. Herein, we report a retrospect-
ive review of the outcome and toxicity in these patients.Methods
Patients
Fourteen patients with neuroblastoma received PBT at
21 sites from 1984 to 2010 at our institute. The patient
characteristics are shown in Table 1. The patients were 6
boys and 8 girls with a median age of 3 years old (range
1 to 6 years old). PBT was conducted because photon
beam radiotherapy was difficult due to a large irradiation
area involving normal organs such as the liver, heart,
and gastrointestinal tract for 8 patients (Nos. 1–3, 6, 7,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Background of 14 patients treated with proton beam therapy
Patient
No
Age at
PBT
Risk INSS
stage
Site Surgery Gross residual
disease at PBT
PBT dose
(GyE)
Port No. Sedation Respiratory
gating
X-ray
1 1 Unknown 3 upper abdomen open biopsy Yes 28.6 1 yes no none
2 2 High 4 retroperitoneum complete resection No 19.8 1 yes yes Photon for femoral bone
3 6 High 3 mediastinum None Yes 30.6 3 no yes Electron for axillary LN and skull
4 5 High 3 Paranasal sinus None No 19.8 2 no no Photon for whole neck LN
5 3 High 4 paravertebra partial removal Yes 39.6 1 no yes none
6 3 High 4 retroperitoneum partial removal Yes 30.6 2 no yes none
7 5 High 4
retroperitoneum partial removal Yes 30.6 2
no
yes
none
skull base None No 19.8 2 no
8 2 High 4
retroperitoneum partial removal No 19.8 2
yes
yes
noneskull None Yes 19.8 1 no
orbit None Yes 19.8 1 no
9 3 High R* orbit none Yes 43.7 1 yes no Cobalt for neck LN
10 6 High R
paravertebra None Yes 45.5 2
no
no
none
mediastinal node None Yes 45.5 2 yes
11 6 High R
skull base None Yes 33.7 2
no
no
none
occipital bone None Yes 33.7 2 no
12 2 Intermediate R retroperitoneum none Yes 41.4 2 yes yes Post IORT 12Gy
13 2 High R retroperitoneum None Yes 41.4 2 yes yes Post IORT 12Gy
paraaorta LN† None Yes 30.6 2 yes
none14 6 Intermediate R supraclavicular LN None Yes 30.6 1 no no
acetabulum None Yes 30.6 2 no
*R: recurrent disease, †LN: lymph nodes.
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for reduction of the dose to the eyes for 4 patients with
orbital, paranasal sinus and skull base disease (Nos. 4, 8,
9, 11). The other 2 patients (Nos. 5, 10) received PBT
because of the wishes of their families. All patients had
received chemotherapy before PBT.[2] Eight patients
received PBT as initial treatment, including two with
Stage 3 and six with Stage 4 disease classified by the
International Neuroblastoma Staging System (INSS).
The other 6 patients received PBT for recurrent disease.
Twelve patients of the 14 had gross residual disease.
Eleven patients were classified as high risk (i.e. those
with stage 4 disease aged older than 1 year at diagnosis
or those with stage 3 MYCN-amplified tumors), 2 with
recurrent disease were intermediate risk (i.e. stage 3 dis-
ease aged older than 1 year with favorable histology and
MYCN-non-amplified tumors), and insufficient bio-
logical and histological data were available to determine
the risk group in 1 patient diagnosed in 1982 according
to the international neuroblastoma risk group (INRG)
staging system[15]. The treatment site was the abdomen
and pelvis in 9 cases, head and neck in 7, thorax in 2,
paravertebra in 1, acetabulum in 1, and skull in 1. Five
patients received PBT at multiple sites for primary and
metastatic lesions. Photon radiotherapy was used in
combination with PBT for 3 patients for lymph nodes
and distant metastases. Intraoperative radiotherapy (IORT)
had undergone for the recurrent disease in 2 patients.
Proton therapy
Before treatment, CT images for PBT planning were
obtained at intervals of 2–5 mm in the treatment position.
The interval was determined based on the patient’s age,
height and treatment site. For 10 patients with pelvic and
thoracic disease, the CT image was obtained during the
end expiratory phase using a respiratory gating system, as
described previously [16,17]. The gross tumor volume
(GTV) was defined as the tumor volume after remission
induction chemotherapy for a primary tumor and the
tumor volume before PBT for a recurrent tumor. The clin-
ical target volume (CTV) was defined as the GTV plus a
1.5-cm margin and the PTV was defined as the CTV plus
a 0.5- to 0.7-cm margin, in principle; however, the balance
between toxicity and treatment effect was also taken into
account in determining the CTV. Sedatives were adminis-
tered for 5 patients aged 1 to 3 for planning CT and
treatment.
Between 1994 and 2000, PBT was limited to 4 hours a
day and 120 days a year according to proton beam avail-
ability from the National Laboratory for High Energy
Physics. Beam lines were also limited to fixed vertical and
horizontal beam lines, and patients were immobilized by
Styrofoam box manually-hollowed out for individuals.
From September 2001, the new hospital-based facilitywhich includes rotational gantries, releases adequate
energy proton beams from any direction, using the
respiratory gating for 10 patients with pelvic and thoracic
disease with the body immobilized using an individually
shaped body cast (ESFORM; Engineering System Co.,
Matsumoto). Patients with head and neck tumors were
also immobilized using individually manufactured thermo-
plastic masks. The treatment is provided 5 days in a week.
Respiratory gating was used for the 10 patients with pelvic
and thoracic disease. The photon equivalent dose (GyE)
was defined as the physical dose (Gy) × the relative bio-
logical effectiveness of the proton beam assigned a value
of 1.1. Before each treatment, correct placement of the
patient relative to the radiation field was confirmed fluoro-
scopically. The given doses ranged from 19.8 to 45.5 GyE
(median: 30.6 GyE) in 11 to 23 fractions. In Japan, the
common dose for neuroblastoma with a complete re-
sponse after chemotherapy is 19.8 Gy, and 10.8 Gy was
added for grossly residual disease. In this series, higher
doses were administered for patients with recurrent and
chemotherapy-resistant disease. Patients underwent a rou-
tine physical examination once a week during PBT. After
completion of PBT, patients were followed in combination
with a pediatrician using CT, MRI, 99mTc bone scans, and
131I- and 123I- metaiodobenzylguanidine scintigrams.Statistical analysis
Locoregional failure was defined as tumor progression in
the anatomic compartment that contained the primary
tumor (pelvis, abdomen, thorax, neck). The locoregional
control rate was calculated from the start of PBT to the
date of local failure in the irradiation field, marginal re-
currence, or most recent local progression-free follow
up. Statistical analyses were performed using SPSS soft-
ware (SPSS Inc., Chicago, IL, USA). Acute and late tox-
icities associated with treatments were evaluated using
the National Cancer Institute Common Toxicity Criteria
for Adverse Events (CTCAE) version 4.0.Results
The results for the 14 patients are shown in Table 2. The
median follow-up periods from diagnosis and the start of
PBT were 40 months (M) (range: 17 M-30 years (Y)) and
21 M (5 M-29 Y), respectively, for all patients, and 46 M
(25 M-30 Y) and 30 M (18 M-29 Y), respectively, for sur-
viving patients. The planned irradiation was completed
in all patients. At the time of analysis in 2012, 8 patients
were alive. Of the 8 patients who received PBT as initial
treatment, 6 (75%) were alive with no evidence of disease,
1 was alive with distant metastasis, and 1 had died from
tumor progression. Of the 6 patients who received PBT
for recurrence, 1 was alive with no evidence of disease
and 5 had died from tumor progression. The initial
Table 2 Clinical outcomes in 14 patients treated with proton beam therapy
Patient
No
Cause of
death
Survival after PBT
(M)
Progression Acute toxicity* Late toxicity*
1 alive 349 none none vertebral growth retardation, narrowed
aorta
2 alive 61 none none none
3 alive 40 none none none
4 alive 39 none temporary hair loss, G1
pharyngitis
None
5 tumor 9 bone G1 skin reaction None
6 alive 20 none None G1 skin pigmentation
7 alive 20 bone marrow None none
8 alive 18 none hair loss thin hair
9 tumor 11 brain G1 skin reaction none
10 tumor 11 bone none none
11 tumor 31 bone marrow none none
12 tumor 27 lymph node none none
13 tumor 5 liver none -
14 alive 22 none none none
*G1: Grade 1 according to Criteria for Adverse Events version 3.0 of the National Cancer Institute and the late radiation morbidity scoring scheme of the Radiation
Therapy Oncology Study Group/European Organization for Research and Treatment of Cancer.
Figure 1 Local control rate for all patients.
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liver (n = 1), brain (n = 1), and lymph nodes (n = 1).
Recurrence in the treatment field was not observed,
but marginal failures occurred in 2 patients (Nos. 12,
13), resulting in a 3-year a locoregional control rate of
82% (CI: 59-100%) (Figure 1). One patient (No. 12)
received PBT for a bulky recurrent tumor. This patient
received PBT of 19.8 GyE for the pre-chemotherapy
tumor volume, 30.6 GyE for the gross tumor volume,
and 41.4 GyE for the gross tumor volume excluding the
IORT field (Figure 2). The PTV margins were 5 mm be-
cause of the large irradiation volume. After completion
of PBT, the tumor had disappeared, but paraaortic
lymph node metastases appeared below the first irradi-
ation field 17 months after PBT. This recurrent lesion
was irradiated with about a 40% dose of 19.8 GyE. The
second patient (No. 13) also received PBT for a bulky re-
current tumor invading the hepatic portal region (Fig-
ure 3). The irradiation field was too large to add the
margin of 1.5 cm, and the whole tumor was included in
the treatment field with a margin of 7 mm for the dose
of 30.6 GyE, but the left kidney was blocked after 10.8
GyE. The tumor at the Morison fossa was excluded from
the treatment field after 30.6 GyE by considering toler-
ance of the liver, and the treatment field was reduced to
the main retroperitoneal tumor. The tumor shrunk in
size, but disease progression occurred in the portal
region beyond the irradiation field 5 months after PBT.
No severe acute toxicity was observed. A mild skin
reaction and mucositis occurred in 3 patients and tem-
porary hair loss in 2 as acute toxicity. Late toxicity wasobserved in 2 of the 13 patients who were followed up
for more than 6 months. One of these patients was a neo-
natal case with stage 3 disease who reached adulthood.
Retrospective measurement of the mitosis-karyorrhexis
index (MKI) of pathological samples showed a favorable
histology consistent with International Neuroblastoma
Pathology Committee (INPC) criteria (low MKI and
≤1 year old at diagnosis). The MYCN status was not mea-
sured, but the patient may have been classified into the
intermediate risk group with non-amplified MYCN, based
on her survival. Thus, for a similar contemporary case,
radiotherapy and chemotherapy would have been reduced;
however, pathological and biological data for INRG risk
grouping were not available in 1982 and she received PBT
Figure 2 Dose distribution for patient No.12.
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1 year old. She visited our hospital due to unexplained oc-
casional stomach pain during early pregnancy at 28 years
after the PBT. The pain increased after eating, which
caused loss of appetite. Thus, the patient did not gain
enough weight during pregnancy and this resulted in a
premature birth. A CT scan after birth showed vertebral
growth retardation and a narrowed aorta, including the
celiac artery (Figure 4). The reason for the stomach pain
was concluded to be mesenteric ischemia due to stenosis
of the superior mesenteric artery. Cilostazol was pre-
scribed to increase blood flow and her stomach pain was
relieved. There were no symptoms caused by vertebral
growth retardation. The other patient received 19.8 GyE
to the skull when he was 2 year old (Figure 5). Hair loss
was prolonged, and his hair has been thin with some whiteFigure 3 Dose distribution for patient No.13.hair from 18 months after PBT. No secondary cancer was
observed.
Discussion
Recent progress of systemic therapies for advanced
neuroblastoma has resulted in improved clinical out-
comes, but local control is still an important concern.
Panandiker et al. suggested that locoregional tumor con-
trol has an influence on overall survival [18], but gross
resection is sometimes difficult because of bulky and in-
vasive features involving critical organs. The prognosis
of neuroblastoma with gross residual disease is poor and
control is difficult, with Kushner et al. finding local re-
currence in 3 of 7 patients with residual disease [3].
Neuroblastoma is highly sensitive to radiotherapy and a
relatively low radiation dose of approximately 20 Gy is
Figure 4 CT scan 28 years after the PBT. (A) Growth retardation in the ventral vertebral body. (B) Narrowing of the aorta below the
irradiated field.
Figure 5 Proton irradiation of the skull reduces the dose to
brain tissue.
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the necessity for an escalated dose for gross residual dis-
ease has been suggested [19,20]. Kogan et al. reported an
estimated 5-year locoregional recurrence rate of 51% for
high risk primary neuroblastoma treated with 10 Gy for
residual disease [19]. Compared with this, local recur-
rence was not observed in the patients with primary dis-
ease in our study, even though most patients had gross
residual disease that was considered to be difficult to
control by photon radiotherapy.
Recurrent neuroblastoma is also difficult to control, and
sometimes acquires resistance to chemotherapy. Local
radiotherapy for recurrent neuroblastoma has not been
established. In our cases, most recurrent tumors were too
large to be treated by photon radiotherapy, but around
20 Gy seemed to be insufficient for these tumors.
Therefore, we treated 6 patients with recurrent disease
using PBT with escalated doses from 30.6 to 45.5 GyE.
Most of the patients eventually died, but 5 of the 6 had
had an immediate complete response, with 2 surviving for
more than 2 years after PBT and 1 patient still alive with
no evidence of recurrence. These results suggest that PBT
may contribute to improvement of the prognosis of
patients with recurrent disease.
PBT is considered to be superior to intensity modu-
lated radiation therapy (IMRT) for pediatric patients
because higher doses can be delivered homogeneously to
a large volume of neuroblastoma with a small number ofports while delivering very low doses in the path of the
beam, which minimize the risk of a secondary cancer
due to peripheral doses [10,12]. Hillbrand et al. sug-
gested that PBT for pelvic neuroblastoma was preferred
over IMRT because the dose distribution in IMRT pro-
duced a 1.5-fold greater risk of adverse events compared
to PBT [10]. However, it is still important to monitor
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toxicities in 2 patients. Follow-up is particularly import-
ant for girls for whom the aorta was included in the
treatment field in PBT and photon radiotherapy because
this may affect a future pregnancy. The threshold of aor-
tic retardation is unclear; therefore, irradiation of the
aorta should be avoided as much as possible by taking
advantage of the proton dose distribution. Thus, the in-
dication for PBT and photon radiotherapy in infancy
should be carefully considered. Hair loss is generally
only a minor problem after photon radiotherapy at
20 Gy, but this effect was prolonged in one of our
patients. This may be because proton beams do not have
a build-up effect and doses at the skin surface are higher
than those in photon radiotherapy when the target is lo-
cated near the surface. We choose proton as an alterna-
tive to electron beams to reduce cranial doses, but hair
follicles are located 4 mm deep in the skin and the lethal
dose for hair follicles is 16 Gy [21]. This indicates that
the treatment field and indication should be carefully de-
termined to optimize the utilization of the characteristics
of proton beams.
Until recently, PBT was viewed as a novel therapy, and
therefore we had mainly used PBT to treat patients with
neuroblastoma that was difficult to manage, with most
of these patients having gross residual disease. Manage-
ment with photon radiotherapy was difficult in 8 of the
14 patients in the study and PBT was chosen as a poten-
tial treatment option. The outcomes in these cases were
favorable and little severe toxicity occurred, even though
higher doses (> 20 Gy) were used for some patients. Our
study is limited by the small number of patients and re-
striction of long-term follow-up to only one patient, but
the results suggested that PBT may be conducted safely
for patients with neuroblastoma that is difficult to
manage using photon beams.
Conclusions
PBT may be conducted safely for patients with neuro-
blastoma that is difficult to manage using photon beams.
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